Development of a standardized commercial test to “score” patients as eligible for active surveillance

A new paper to be presented at the Genitourinary Prostate Cancer Symposium has proposed development of a standardized method to “score” whether patients are suitable candidates for initial management on active surveillance. … READ MORE …

Prolaris test data change clinician, patient decisions about prostate cancer management

A new paper in the Journal of Urology provides us with some interesting if preliminary information on the ways that genetic/genomic tests of biopsy samples may be affecting first-line treatments for localized forms of prostate cancer. … READ MORE …

Can Prolaris test accurately predict risk for prostate cancer-specific mortality?

Data to be presented at the upcoming meeting of the American Society of Clinical Oncology addresses the potential of the Prolaris™ test (developed by Myriad Genetics, Inc.) to predict which men being followed under an active surveillance protocol are at greatest risk of dying from prostate cancer at 10 years of follow-up. … READ MORE …

Is CCP testing really the prognostic tool we need?

A new report just published on line in Lancet Oncology is suggesting that the cell cycle progression (CCP) score — a measure of the levels of expression of selected genes that are important to cell growth — may be an important indicator of risk for more aggressive types of prostate cancer. … READ MORE …